Seidel C - Search Results

1

Retrospective analyses of patient characteristics having predictive impact on survival under everolimus.

Seidel C, Fenner M, Reuter C, Merseburger AS, Ganser A, Grünwald V. Seidel C, et al. Onkologie. 2011;34(3):111-4. doi: 10.1159/000324668. Epub 2011 Feb 15. Onkologie. 2011. PMID: 21358215

2

Recall pneumonitis during systemic treatment with sunitinib.

Seidel C, Janssen S, Karstens JH, Welte T, Morgan M, Ganser A, Grünwald V. Seidel C, et al. Ann Oncol. 2010 Oct;21(10):2119-2120. doi: 10.1093/annonc/mdq444. Epub 2010 Aug 18. Ann Oncol. 2010. PMID: 20720089 Free article. No abstract available.

3

Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients.

Seidel C, Fenner M, Merseburger AS, Reuter C, Ivanyi P, Länger F, Ganser A, Grünwald V. Seidel C, et al. World J Urol. 2011 Jun;29(3):355-60. doi: 10.1007/s00345-010-0642-3. Epub 2011 Jan 22. World J Urol. 2011. PMID: 21258806

4

[Use of mTOR-inhibitors in solid tumors].

Seidel C, Grünwald V. Seidel C, et al. Med Monatsschr Pharm. 2011 Apr;34(4):116-26; quiz 127-8. Med Monatsschr Pharm. 2011. PMID: 21528529 Review. German.

5

Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC.

Grünwald V, Weikert S, Seidel C, Busch J, Johannsen A, Fenner M, Reuter C, Ganser A, Johannsen M. Grünwald V, et al. Among authors: seidel c. Onkologie. 2011;34(6):310-4. doi: 10.1159/000328575. Epub 2011 May 6. Onkologie. 2011. PMID: 21625184

6

Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.

Busch J, Seidel C, Weikert S, Wolff I, Kempkensteffen C, Weinkauf L, Hinz S, Magheli A, Miller K, Grünwald V. Busch J, et al. Among authors: seidel c. BMC Cancer. 2011 Jul 14;11:295. doi: 10.1186/1471-2407-11-295. BMC Cancer. 2011. PMID: 21756335 Free PMC article.

7

Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.

Busch J, Seidel C, Kempkensteffen C, Johannsen M, Wolff I, Hinz S, Magheli A, Miller K, Grünwald V, Weikert S. Busch J, et al. Among authors: seidel c. Eur Urol. 2011 Dec;60(6):1163-70. doi: 10.1016/j.eururo.2011.07.037. Epub 2011 Jul 21. Eur Urol. 2011. PMID: 21802830

8

Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy?

Steffens S, Grünwald V, Ringe KI, Seidel C, Eggers H, Schrader M, Wacker F, Kuczyk MA, Schrader AJ. Steffens S, et al. Among authors: seidel c. Oncologist. 2011;16(11):1565-71. doi: 10.1634/theoncologist.2011-0213. Epub 2011 Oct 21. Oncologist. 2011. PMID: 22020210 Free PMC article.

9

Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies.

Grünwald V, Seidel C, Fenner M, Ganser A, Busch J, Weikert S. Grünwald V, et al. Among authors: seidel c. Br J Cancer. 2011 Nov 22;105(11):1635-9. doi: 10.1038/bjc.2011.389. Epub 2011 Oct 27. Br J Cancer. 2011. PMID: 22033275 Free PMC article. Clinical Trial.

10

Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.

Seidel C, Busch J, Weikert S, Steffens S, Fenner M, Ganser A, Grünwald V. Seidel C, et al. Eur J Cancer. 2012 May;48(7):1023-30. doi: 10.1016/j.ejca.2012.02.048. Epub 2012 Mar 20. Eur J Cancer. 2012. PMID: 22436979

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

632 results

Search Page

Filters